Italy, Germany, France and the Netherlands have formed an alliance to secure the vaccine for Europe. After running the risk of being left on the sidelines, the Italian government has signed a contract with AstraZeneca for 400 million doses. The vaccine, developed by the Oxford University in collaboration with the Italian company IRBM (located in Pomezia, Rome) through its vaccines division Advent, has been chosen as vaccine candidate. Results of phase I trials will be disclosed in 10 days.
Article published on ilmessaggero.it – 15/06/2020
Read the original article on ilmessaggero.it